GLP1R and type 2 diabetes mellitus: In addition, in light of the efficacy showed by SGLT2i and glucagon-like-peptide-1 receptor agonists (GLP1ra) in improving cardiovascular outcomes in patients with T2D and in those with high risk for cardiovascular disease [26], future studies should be conducted to investigate the impact of national and international guidelines on prescription patterns of these therapeutic drug classes in GPs setting.